Screener
Bioventus BVS D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Selling, general and administrative expense | 82,740 | 79,110 | 161,065 | 152,612 |
| Research and development expense | 3,173 | 3,172 | 5,640 | 6,183 |
| Restructuring costs | (415) | — | 39 | — |
| Depreciation and amortization | 1,041 | 1,439 | 2,148 | 3,032 |
| Loss on disposals | — | 1 | — | 82 |
| Operating income | 19,127 | 18,368 | 27,543 | 23,237 |
| Interest expense, net | 4,068 | 7,494 | 8,394 | 15,003 |
| Other (income) expense | (249) | 561 | (676) | 1,338 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's D&A?
- Bioventus (BVS) reported D&A of $1.04M in Q2 2026.
- How has Bioventus's D&A changed year-over-year?
- Bioventus's D&A decreased by 27.7% year-over-year, from $1.44M to $1.04M.
- What is the long-term trend for Bioventus's D&A?
- Over 4 years (2021 to 2025), Bioventus's D&A has grown at a -9.0% compound annual growth rate (CAGR), from $8.36M to $5.73M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Bioventus's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude